Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Stomach bug treatment may relieve chronic gut discomfort

NCT ID NCT07272681

Disease control Sponsor: Amany Usama Ahmed Arafa Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will test whether standard treatment to eliminate H. pylori bacteria can improve ongoing stomach and gut symptoms in 100 adults. Participants will receive antibiotics and acid-reducing medication, and their symptoms will be tracked using a questionnaire. The goal is to see if successful eradication leads to meaningful symptom relief.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
standard Helicobacter pylori eradication therapy (antibiotics and acid-reducing medication)
What this could lead to
If successful, this could confirm that eradicating H. pylori reliably reduces common stomach and gut symptoms, offering a clear treatment path for many patients.
What could go wrong
This is a small, early-stage study without a placebo group, so symptom improvement could be due to other factors. Eradication therapy can also cause side effects like nausea or diarrhea.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients (≥18 years) diagnosed with Helicobacter pylori infection by invasive or non-invasive tests (urea breath test or stool antigen test) and who have completed standard eradication therapy prescribed by their healthcare providers. The population includes both male and female patients presenting with gastrointestinal symptoms such as dyspepsia.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults aged 18 years and older. 2. Confirmed diagnosis of Helicobacter pylori infection by one or more diagnostic tests. 3. Presence of any upper or lower gastrointestinal symptoms. 4. Willingness to undergo H. Pylori eradication therapy and follow-up. 5. Ability to provide informed consent. Exclusion Criteria: 1. Age less than 18 years. 2. The previously unsuccessful application of empirical H. pylori eradication therapy. 3. Use of non-steroidal anti-inflammatory drugs (NSAIDs). 4. Any malignant disease of the stomach or any other site. 5. Any associated comorbidity (renal insufficiency, mental illness). 6. History of allergies to proton pump inhibitors or antibiotics. 7. Refusal to participate in the survey.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dyspepsia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

dyspepsia Helicobacter pylori infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dyspepsia Gastrointestinal symptoms Helicobacter pylori infection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.